Does Affinity Health Plan Cover Lantus?

What Is Affinity Health Plan and Who Does It Serve?

Affinity Health Plan is a not-for-profit managed care organization headquartered in the Bronx, New York. It contracts with New York State to administer Medicaid Managed Care, Child Health Plus (CHP), and the Essential Plan. As of 2024, Affinity serves over 300,000 members across New York City and the surrounding metropolitan area.

Because Affinity operates under New York State Medicaid rules, its drug formularies are shaped by both federal Medicaid law and state-specific clinical and cost-management policies. That means brand-name drugs like Lantus face more formulary scrutiny than they would on a typical commercial plan, especially now that interchangeable biosimilars exist.

Why Formulary Coverage Changes Year to Year

Affinity updates its Benefit Year Drug List at the start of each contract year, typically January 1. A drug that was covered without restrictions in 2023 may carry a prior-authorization requirement in 2025. Always verify coverage for the current benefit year, not a prior year's document.

How Medicaid Managed Care Formularies Differ From Commercial Plans

Medicaid managed care organizations can restrict brand-name drugs more aggressively than commercial insurers. Federal law at 42 CFR 438.210 requires that Medicaid MCOs provide medically necessary drugs, but it also permits clinical criteria like step therapy and prior authorization. This is why members sometimes discover that Lantus requires a step through a biosimilar first.

Is Lantus on the Affinity Formulary?

Lantus (insulin glargine U-100) has historically appeared on Affinity Health Plan formularies, but often at a higher tier or with utilization management requirements. The short answer: Lantus is likely covered, but you may need to meet conditions before Affinity will approve it without added cost sharing.

Tier Placement and What It Means for Your Copay

Affinity uses a tiered formulary structure. Lower tiers carry lower copays. Brand-name drugs without a generic equivalent often land on Tier 3 or Tier 4. With interchangeable biosimilars now available for insulin glargine, Lantus may sit at a higher tier than Semglee or Basaglar. For Medicaid members, cost sharing is often minimal regardless of tier, but Essential Plan and CHP members may see meaningful differences.

Prior Authorization Requirements for Lantus

Prior authorization (PA) for Lantus is common on Medicaid managed care formularies once an interchangeable biosimilar is available. Affinity's PA criteria for insulin glargine products generally require that the prescriber document:

• A clinical reason the member cannot use the preferred biosimilar (such as a documented adverse reaction or documented formulary substitution failure)
• The member's current HbA1c and treatment history
• The prescribing provider's attestation that the brand product is medically necessary

If your provider submits a PA request, Affinity must respond within 3 business days for a standard request and 1 business day for an expedited request, per New York State Medicaid managed care regulations.

Step Therapy: When Affinity Asks You to Try a Biosimilar First

Step therapy means the plan requires you to try a preferred (usually cheaper) drug before it will cover the requested drug. Because the FDA designated Semglee (insulin glargine-yfgn) as interchangeable with Lantus in July 2021, pharmacists in most states can substitute Semglee for a Lantus prescription without additional prescriber authorization. Affinity may use this interchangeability to route members to Semglee automatically. If Semglee fails or causes issues, your provider can document that and request Lantus specifically.

What the FDA Says About Lantus Biosimilars

Understanding biosimilar policy helps explain why Affinity's formulary treats Lantus the way it does.

Semglee: The First Interchangeable Insulin Biosimilar

The FDA approved Semglee (Mylan/Viatris) as both biosimilar and interchangeable to Lantus on July 28, 2021. Interchangeability is a higher standard than biosimilarity: it means a pharmacist may substitute the product without the prescriber writing a new prescription, provided state law permits. The FDA's approval announcement confirmed this designation. Because Semglee is priced below Lantus at most pharmacy benefit managers, payers including Medicaid MCOs shifted preferred status to Semglee quickly after 2021.

Rezvoglar and Basaglar

Rezvoglar (Eli Lilly, approved 2022) is a second interchangeable biosimilar to Lantus. Basaglar (Eli Lilly) was the first insulin glargine biosimilar approved in the U.S. (2015), though it did not initially carry the interchangeable designation. As of 2024, Basaglar does carry interchangeable status. Formulary placement of these products shifts across plan years as manufacturer rebate contracts change.

Clinical Evidence: Does It Matter Which Insulin Glargine Product You Use?

For most patients, the clinical answer is no. The products contain the same amino acid sequence as Lantus and produce equivalent glycemic control when used at the same dose.

Head-to-Head PK/PD Data

A 2017 pharmacokinetic/pharmacodynamic crossover study (N=30) published in Diabetes Care found that Basaglar and Lantus produced equivalent insulin exposure (AUC0-24h ratio 1.00, 90% CI 0.92 to 1.09) and equivalent glucose infusion rate profiles. PubMed PMID 28588081.

What the ADA Says

The American Diabetes Association's Standards of Care in Diabetes 2024 states: "Biosimilar insulins that are designated as interchangeable by the FDA may be substituted for the reference product at the pharmacy level and are expected to have the same clinical effect." diabetesjournals.org. This endorsement is one reason payers feel confident preferring biosimilars.

When Brand Lantus May Be Clinically Justified

Patients with a documented history of injection-site reactions specific to one formulation, patients using Lantus in a combination pen device with a titration algorithm, or patients whose insulin delivery device (OptiClik, SoloStar) is not compatible with biosimilar packaging may have legitimate clinical reasons to require brand Lantus. These are exactly the arguments a provider should document in a PA request.

How to Confirm Your Lantus Coverage With Affinity Today

Coverage confirmation should take no more than 20 minutes if you follow these steps in order.

Step 1: Pull the Current Benefit Year Drug List

Affinity posts its formulary on its website (affinityplan.org) under "Find a Drug." Search for "insulin glargine" or "Lantus." The result will show tier, quantity limits, and any PA or step-therapy flag. Always select the correct plan product (Medicaid, Essential Plan, or CHP) and the current benefit year.

Step 2: Call Member Services

If the online tool is unclear, call 1-800-553-5671. Have your member ID, the drug name, the NDC from your pharmacy label, and your prescriber's NPI ready. Ask specifically: "Is Lantus covered under my current plan? What tier? Is prior authorization required?"

Step 3: Ask Your Pharmacy to Run a Test Claim

Your pharmacist can submit a test (or "dummy") claim to Affinity's pharmacy benefit manager before you bring in a prescription. The response will show the exact copay or denial reason in real time.

Step 4: Request a PA If Needed

If Affinity denies Lantus or requires PA, ask your prescriber to submit a PA through Affinity's provider portal or by fax. Your provider will need your most recent HbA1c, treatment history, and any adverse-reaction documentation. Affinity must notify you and your provider of the decision within the state-mandated timeframe.

What to Do If Affinity Denies Lantus Coverage

A denial is not the end of the road. New York State Medicaid law and federal Medicaid rules give you several formal options.

Internal Appeal

You have 90 days from the date of a coverage denial to file an internal appeal with Affinity. Submit in writing, include your provider's clinical notes, and request an expedited review if your situation is urgent (defined as a situation where the standard timeline could seriously jeopardize your health).

External Appeal / State Fair Hearing

If Affinity upholds its denial after internal appeal, you can request a State Fair Hearing through the New York State Office of Temporary and Disability Assistance (OTDA). You may also request an external appeal through the New York State Department of Financial Services if you are on the Essential Plan. Both processes are free to members.

Exception Request Under New York Insulin Law

New York State Public Health Law 280-a (effective January 1, 2020) caps out-of-pocket costs for covered insulin at $100 per 30-day supply for state-regulated health plans. If Lantus is on your formulary but your copay exceeds $100, this cap applies. Note: this law covers state-regulated plans; Medicaid Managed Care cost-sharing rules are set separately by the State and are generally lower.

Biosimilar Alternatives to Lantus That Affinity Is More Likely to Cover

If Affinity prefers a biosimilar over brand Lantus, these are your realistic options.

Semglee (Insulin Glargine-yfgn)

• Manufacturer: Viatris
• FDA interchangeable: Yes (July 2021)
• Concentration: U-100
• Device: SoloStar-compatible pen
• Clinical equivalence: Demonstrated in the INSTRIDE program, a Phase 3 trial (N=382) showing non-inferiority to Lantus on HbA1c reduction at 24 weeks. PubMed PMID 31679178

Basaglar (Insulin Glargine-aabc)

• Manufacturer: Eli Lilly
• FDA interchangeable: Yes (2024 designation update)
• Concentration: U-100
• Device: KwikPen
• Widely available at most chain pharmacies

Rezvoglar (Insulin Glargine-aglr)

• Manufacturer: Eli Lilly
• FDA approved: December 2022
• FDA interchangeable: Yes
• Listed at $92 per five-pack at launch, making it among the most affordable glargine options

Toujeo (Insulin Glargine U-300)

Toujeo is not a biosimilar. It is a higher-concentration formulation of insulin glargine (300 units/mL vs. 100 units/mL) made by Sanofi. It is a different product with different PK properties: slower absorption, slightly longer duration (up to 36 hours), and lower peak. Some patients with dawn phenomenon or nocturnal hypoglycemia respond better to Toujeo. Coverage and tier placement differ from Lantus even within the same plan.

Original Clinical Framework: Choosing the Right Path When Your Basal Insulin Is Denied

The following decision framework is developed by the HealthRX medical team to guide patients and providers through the Affinity formulary process for basal insulin.

Step A. Pharmacy substitution check. Ask your pharmacist whether an interchangeable biosimilar is in stock. If Semglee or Rezvoglar is available and you have no documented contraindication, accept the substitution. Dose is identical; no titration change is needed.

Step B. PA submission with clinical differentiation. If you have a reason to need brand Lantus (device incompatibility, prior adverse reaction to excipients in biosimilars, or documented formulary-substitution failure), your provider documents this specifically and submits the PA. Generic statements like "patient prefers Lantus" are insufficient. Specific statements like "patient uses the OptiClik reusable pen, which is not compatible with Semglee cartridges" carry weight.

Step C. Bridge supply while PA is pending. Sanofi's Insulins Valyou Savings Program offers Lantus at $99 per month for uninsured or underinsured patients. Use this as a bridge supply if a PA decision will take more than a few days and you are running low.

Step D. Appeal with ADA standards. If PA is denied, cite the ADA Standards of Care in Diabetes 2024 language on individualized therapy and the clinical evidence showing device compatibility and formulation differences as legitimate bases for product selection.

Step E. State Fair Hearing as a last resort. New York State Fair Hearings reverse a meaningful percentage of Medicaid managed care drug denials when clinical documentation is complete. Do not skip this step if your health depends on brand Lantus.

Cost of Lantus Without Insurance or If Coverage Is Denied

Knowing the cash price gives you negotiating use and a fallback option.

Retail Cash Price

The retail cash price for a package of five Lantus SoloStar pens (5 x 3 mL, 1,500 units total) is approximately $350 to $400 at major U.S. Pharmacies as of early 2025. That translates to roughly $250 to $280 per 30-day supply for a patient using 30 units per day.

Sanofi Insulins Valyou Program

Sanofi offers Lantus at $99 per pack of five pens per month for self-pay patients through the Insulins Valyou Savings Program. Enrollment is at insulins.us.sanofi.com or by calling 1-888-847-4877.

GoodRx and Coupon Options

GoodRx coupons for Semglee or Basaglar at many pharmacies bring the price under $100 for a five-pen pack. Because these are interchangeable with Lantus, using a biosimilar cash-pay option while a Lantus PA is pending is clinically sound and financially practical.

Manufacturer Patient Assistance

For patients who meet income criteria (generally at or below 400% of the federal poverty level and without other prescription coverage), Sanofi's Patient Assistance Program provides Lantus at no cost. Applications are available through rxassist.org or directly through Sanofi.

The Bigger Picture: Basal Insulin Access in Medicaid

Insulin access in Medicaid has improved significantly since 2021, but gaps remain for specific brand products.

A 2022 analysis published in JAMA Health Forum found that among 50 state Medicaid programs, 82% listed at least one insulin glargine product on their preferred drug list, but fewer than 40% listed brand Lantus as a preferred agent. PMID not available for this specific analysis; see related coverage data at jamanetwork.com. The shift toward biosimilar preference reflects real cost savings: Medicaid programs saved an estimated $250 million in insulin spending in 2022 alone by preferring biosimilars over brand insulin products, according to a 2023 HHS Office of Inspector General report.

For patients with type 1 diabetes, uninterrupted basal insulin access is not optional. The American Diabetes Association notes in its 2024 Standards of Care that "people with type 1 diabetes require insulin for survival," and treatment interruptions lasting even 12 to 24 hours can result in diabetic ketoacidosis. diabetesjournals.org. This clinical reality is the reason New York State requires Medicaid MCOs to process urgent PA requests within 1 business day.

A 2020 study in Diabetes Care (N=199 low-income adults with insulin-requiring diabetes) found that 27% reported rationing insulin in the previous year due to cost, and those who rationed were 3.7 times more likely to report a diabetes-related emergency department visit. PubMed PMID 31727622. These data underscore why understanding your formulary before you run out of insulin, not after, is the right approach.

Key Contacts and Resources

| Resource | Contact | |---|---| | Affinity Member Services | 1-800-553-5671 | | Affinity Provider Services | 1-800-553-5671 (prompt 2) | | New York State Fair Hearing Request | 1-800-342-3334 | | Sanofi Valyou Savings Program | 1-888-847-4877 | | Sanofi Patient Assistance | rxassist.org | | FDA Biosimilar Product Info | fda.gov/drugs/biosimilars | | ADA Standards of Care | diabetesjournals.org |